Get the Stockscreener App
0.7187
0.97%
0.0069
Pre-market:
.72
0.0013
+0.18%
Tenaya Therapeutics Inc stock is traded at $0.7187, with a volume of 2.11M.
It is up +0.97% in the last 24 hours and down -16.17% over the past month.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
See More
Previous Close:
$0.7118
Open:
$0.74
24h Volume:
2.11M
Relative Volume:
0.56
Market Cap:
$155.96M
Revenue:
-
Net Income/Loss:
$-83.01M
P/E Ratio:
-1.5253
EPS:
-0.4712
Net Cash Flow:
$-64.63M
1W Performance:
+4.71%
1M Performance:
-16.17%
6M Performance:
-9.82%
1Y Performance:
+21.50%
1-Day Range:
$0.7121
$0.74
1-Week Range:
$0.675
$0.74
52-Week Range:
$0.5316
$2.35
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Name
Tenaya Therapeutics Inc
Sector
Industry
Phone
415-865-2066
Address
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.7187 | 155.96M | 0 | -83.01M | -64.63M | -0.4712 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-24 | Initiated | William Blair | Outperform |
| Nov-30-23 | Initiated | Leerink Partners | Outperform |
| Jun-15-22 | Initiated | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Stock (TNYA) Latest News
symbol__ Stock Quote Price and Forecast - CNN
Tenaya Therapeutics (TNYA) Q1 2026 Earnings: EPS Miss Reflects R&D Investment as Company Advances PipelineNegative Surprise Momentum - newsline.com
TNYA News | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
TNYA Q1 2026 Earnings: Slightly Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineMid-Term Outlook - newsline.com
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
Morgan Stanley Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $2 - Moomoo
A Quick Look at Today's Ratings for Tenaya Therapeutics(TNYA.US), With a Forecast Between $2 to $4 - Moomoo
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCMSlideshow (NASDAQ:TNYA) 2026-06-03 - Seeking Alpha
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in... - markets.businessinsider.com
Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms - TradingView
Tenaya reports interim data from gene therapy trial for rare heart condition - Investing.com
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms - The Manila Times
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym - StreetInsider
Gene therapy eases genetic heart condition in small Tenaya trial - Stock Titan
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 - The Manila Times
Tenaya Therapeutics to Announce New Interim Data from MyPEAK-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 - Investing News Network
Tenaya to present gene therapy trial data Wednesday By Investing.com - Investing.com South Africa
Tenaya to present gene therapy trial data Wednesday - Investing.com
Tenaya Therapeutics to Report Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 Gene Therapy for HCM on June 3, 2026 - Quiver Quantitative
Tenaya Therapeutics to Announce New Interim Data from - GlobeNewswire
Tenaya Therapeutics, Inc. Announces Amended and Restated 2021 Equity Incentive Plan and SEC Filing Details - Minichart
Tenaya Therapeutics (TNYA) director granted 120,000 options at $0.7989 strike - Stock Titan
Tenaya director granted options for 120,000 shares | TNYA Insider Trading - Stock Titan
Tenaya Therapeutics (TNYA) director receives 120,000 stock options at $0.7989 - Stock Titan
Tenaya Therapeutics (TNYA) awards director 120,000 options at $0.7989 - Stock Titan
Tenaya (TNYA) director receives 120K stock options at $0.7989 - Stock Titan
Tenaya Therapeutics (TNYA) director June Lee granted 120,000 stock options - Stock Titan
Tenaya Therapeutics (TNYA) director receives 120,000 stock options grant - Stock Titan
Tenaya Therapeutics (NASDAQ: TNYA) boosts share pool in revised equity plan - Stock Titan
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026 - Investing News Network
Tenaya Therapeutics to Present at Jefferies Global Healthcare Conference on May 29, 2026 - geneonline.com
Tenaya Therapeutics to present at Jefferies Global Healthcare Conference 2026 in June - Pluang
Tenaya Therapeutics to Present at Jefferies Global Healthcare Conference June 2026 - Quiver Quantitative
Tenaya Therapeutics Q1 2026 Earnings: Narrow Miss on Earnings as Biotech Firm Reports No RevenueEPS Miss Report - newsline.com
What do we know so far from TN-201 trial? - Moomoo
TN-201 and TN-401 - Moomoo
TNYA Technical Analysis | Trend, Signals & Chart Patterns | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
Tenaya Therapeutics' gene therapy data highlights early heart rhythm improvements - MSN
Tenaya Therapeutics CMO Tingley Whittemore sells $2,476 in stock By Investing.com - Investing.com Australia
Tenaya Therapeutics CEO Ali Faraz sells $2,689 in shares By Investing.com - Investing.com Australia
Tenaya Therapeutics CEO Ali Faraz sells $2,689 in shares - Investing.com UK
Tenaya Therapeutics CMO Tingley Whittemore sells $2,476 in stock - Investing.com UK
Tenaya Therapeutics SVP Tomohiro Higa reports $1,177 stock sale - Investing.com UK
Tenaya Therapeutics SVP Tomohiro Higa reports $1,177 stock sale By Investing.com - Investing.com India
Tenaya (TNYA) CEO sells 3,390 shares tied to RSU tax withholding - Stock Titan
Tenaya Therapeutics (TNYA) CMO sells 3,121 shares for tax withholding - Stock Titan
Tenaya Therapeutics (TNYA) SVP sells 1,485 shares to cover RSU taxes - Stock Titan
Canaccord Genuity Sticks to Their Buy Rating for Tenaya Therapeutics (TNYA) - The Globe and Mail
Tenaya Therapeutics, Inc. (TNYA) reports Q1 loss, misses revenue estimates - MSN
Tenaya Therapeutics Inc Stock (TNYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):